Allogene Therapeutics (ALLO) Depreciation & Amortization (CF) (2018 - 2026)

Allogene Therapeutics has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $2.9 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 7.42% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (down 7.68% YoY) and the FY2025 annual result came in at $12.4 million, down 9.08% from the prior year.
• Depreciation & Amortization (CF) eased to $2.9 million in Q1 2026 per ALLO's latest filing, from $3.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $3.9 million in Q3 2022 and troughed at $2.9 million in Q1 2026.
• A 5-year average of $3.4 million and a median of $3.5 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 92.49% in 2022, down 27.68% in 2022.
• Over 5 years, Depreciation & Amortization (CF) stood at $3.1 million in 2022, then gained by 13.33% to $3.5 million in 2023, then retreated by 7.02% to $3.2 million in 2024, then retreated by 4.18% to $3.1 million in 2025, then retreated by 7.39% to $2.9 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.9 million, $3.1 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.